Rituximab for children with immune thrombocytopenia: a systematic review.
BACKGROUND: Rituximab has been widely used off-label as a second line treatment for children with immune thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and interpret the available evidence, we conducted a systematic review to assess...
Main Authors: | Yi Liang, Lingli Zhang, Ju Gao, Die Hu, Yuan Ai |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3364261?pdf=render |
Similar Items
-
Response to rituximab in children and adults with immune thrombocytopenia (ITP)
by: Emily M. Harris, et al.
Published: (2021-08-01) -
Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia
by: Khalid Al-Habsi, et al.
Published: (2015-03-01) -
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01) -
Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis
by: Jia Wang, et al.
Published: (2018-01-01) -
Immune Thrombocytopenia in Children
by: L. Ya. Dubey, et al.
Published: (2013-05-01)